Does the drug artesunate show activity against Cytomegalovirus in immunocompromised patients?

Artesunate is a drug best known for treating malaria. In the lab, it also has real activity against cytomegalovirus (CMV), the virus that causes serious illness in people with weakened immune systems, such as transplant recipients and newborns ⁶⁹. The catch is that lab success has not translated into clear, reliable success in patients. A 2025 systematic review of 46 studies found that clinical evidence for artesunate against CMV is limited, coming mostly from small studies and combination treatments, with inconsistent results ⁶. So the honest answer is: promising in the test tube, unproven in people.

What the research says

Laboratory work is where artesunate looks strongest. A 2011 study found that artesunate blocked CMV at a very early stage of infection and was about 10 times more active against the virus than its parent compound artemisinin ⁹. Importantly, that same study showed artesunate worked against a range of CMV strains that were resistant to standard treatments, with potency staying within about a two-fold range compared to normal virus ⁹. A 2014 study confirmed that artesunate and its active breakdown product, dihydroartemisinin, both inhibit CMV replication in cultured cells, though the drug converts and degrades quickly in lab conditions ⁷.

What to ask your doctor

• Is artesunate being considered as part of my CMV treatment, and if so, is it in a clinical trial setting?
• What are the current standard treatments for CMV in someone with my level of immune suppression, and what are their risks?
• Could drug resistance be an issue with my CMV infection, and how would that change the treatment plan?
• What does my viral load trend tell us about whether treatment is working?
• Are there any clinical trials studying artesunate or newer CMV drugs that I might qualify for?